147 related articles for article (PubMed ID: 1692250)
1. Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo.
Rostaing-Capaillon O; Casellas P
Cancer Res; 1990 May; 50(10):2909-16. PubMed ID: 1692250
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
Fulton RJ; Tucker TF; Vitetta ES; Uhr JW
Cancer Res; 1988 May; 48(9):2618-25. PubMed ID: 3258546
[TBL] [Abstract][Full Text] [Related]
3. In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain.
Rostaing-Capaillon O; Casellas P
Cancer Immunol Immunother; 1991; 34(1):24-30. PubMed ID: 1722138
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
[TBL] [Abstract][Full Text] [Related]
5. The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins.
Manske JM; Buchsbaum DJ; Vallera DA
J Immunol; 1989 Mar; 142(5):1755-66. PubMed ID: 2465347
[TBL] [Abstract][Full Text] [Related]
6. Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Apr; 44(4):1398-404. PubMed ID: 6142765
[TBL] [Abstract][Full Text] [Related]
7. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
Hara H; Luo Y; Haruta Y; Seon BK
Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
Weil-Hillman G; Runge W; Jansen FK; Vallera DA
Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
[TBL] [Abstract][Full Text] [Related]
9. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
[TBL] [Abstract][Full Text] [Related]
11. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Fulton RJ; Uhr JW; Vitetta ES
Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
[TBL] [Abstract][Full Text] [Related]
13. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin.
Yokota S; Hara H; Luo Y; Seon BK
Cancer Res; 1990 Jan; 50(1):32-7. PubMed ID: 2293557
[TBL] [Abstract][Full Text] [Related]
14. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
15. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity.
Pietersz GA; Kanellos J; McKenzie IF
Cancer Res; 1988 Aug; 48(16):4469-76. PubMed ID: 3260814
[TBL] [Abstract][Full Text] [Related]
16. Analysis of gp74 expression by transformed rat fibroblasts from experimental pulmonary metastases following specific ricin A-chain immunotoxin therapy.
Roth JA; Thomsen S; Fry KD; Scannon P; Chang C
Cancer Res; 1989 Oct; 49(20):5708-12. PubMed ID: 2676148
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
[TBL] [Abstract][Full Text] [Related]
18. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
19. Marked difference in the in vivo antitumor efficacy between two immunotoxins targeted to different epitopes of common acute lymphoblastic leukemia antigen (CD10). Mechanisms involved in the differential activities of immunotoxins.
Luo Y; Seon BK
J Immunol; 1990 Sep; 145(6):1974-82. PubMed ID: 1697314
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
